title: [Late cardiac toxicity in Hodgkin's disease. A study with pulsed Doppler echocardiography].
abstract: 49 patients (22 women, 27 men, mean age 43.7 [21-65] years) with Hodgkin's disease were examined by Doppler echocardiography a median of 5.37 (2-10) years after the end of chemotherapy (given according to the COPP/ABVD scheme, with or without mediastinal irradiation) for possible chronic changes in myocardium, pericardium or cardiac valves, as well as for any haemodynamic sequelae. Maximal and integrated early (E, Ei) and late (A, Ai) diastolic flow velocities and their ratio (E/A, Ei/Ai) were measured by pulsed Doppler over the mitral and tricuspid valves. Although on two-dimensional echo 21 patients (42.9%) were found to have valvar thickening, 19 (38.8%) pericardial thickening and 9 (18.4%) a reduced fibre shortening fraction, the Doppler indices were statistically not significantly different from those in 25 controls with normal hearts. These echocardiographic data of functional and morphological parameters indicate that there was no effect on various measurements of diastolic function after chemotherapy with or without mediastinal radiation. In successfully treated patients with Hodgkin's disease the described changes are of minor significance.
authors.affiliation: Abteilung für Innere Medizin mit Schwerpunkt Kardiologie und Pulmologie, Freie Universität Berlin.
authors.forename: H
authors.initials: H
authors.lastname: Völler
authors.forename: E D
authors.initials: ED
authors.lastname: Kreuser
authors.forename: A
authors.initials: A
authors.lastname: Uhrig
authors.forename: K
authors.initials: K
authors.lastname: Schröder
authors.forename: C
authors.initials: C
authors.lastname: Behles
authors.forename: E
authors.initials: E
authors.lastname: Thiel
authors.forename: R
authors.initials: R
authors.lastname: Schröder
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001761:Bleomycin / Q000009:adverse effects; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000009:adverse effects; D003606:Dacarbazine / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D015150:Echocardiography, Doppler / Q000295:instrumentation / Q000379:methods / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D006321:Heart / Q000187:drug effects*; D006689:Hodgkin Disease / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000009:adverse effects; D011344:Procarbazine / Q000009:adverse effects; D011879:Radiotherapy Dosage; D012074:Remission Induction; D013997:Time Factors; D014747:Vinblastine; D014750:Vincristine / Q000009:adverse effects
chemical_list: D001761:Bleomycin; D011344:Procarbazine; D014750:Vincristine; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
vernacular_title: Kardiale Spättoxizität bei Morbus Hodgkin. Untersuchung mit der gepulsten Dopplerechokardiographie.